Ilsung Pharmaceuticals Co., Ltd. (003120.KS)
KRW 15970.0
(-0.19%)
KRW 15970.0
(-0.19%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 119.67 Million KRW | -34.17% |
| 2022 | 181.8 Million KRW | 1809.78% |
| 2021 | 9.51 Million KRW | -92.7% |
| 2020 | 130.38 Million KRW | 3.07% |
| 2019 | 126.5 Million KRW | 0.0% |
| 2018 | - KRW | 0.0% |
| 2017 | - KRW | 0.0% |
| 2016 | - KRW | 0.0% |
| 2015 | - KRW | 0.0% |
| 2014 | - KRW | 0.0% |
| 2013 | - KRW | 0.0% |
| 2012 | - KRW | 0.0% |
| 2011 | - KRW | -100.0% |
| 2010 | 2.8 Billion KRW | 0.0% |
| 2009 | - KRW | 0.0% |
| 2008 | - KRW | 0.0% |
| 2007 | - KRW | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 101.31 Million KRW | 0.0% |
| 2024 Q1 | 119.61 Million KRW | -100.0% |
| 2023 Q4 | 119.67 Million KRW | -14.23% |
| 2023 Q1 | 65.74 Million KRW | -63.84% |
| 2023 FY | 119.67 Million KRW | -34.17% |
| 2023 Q3 | 139.53 Million KRW | 129.74% |
| 2023 Q2 | 60.73 Million KRW | -7.62% |
| 2022 Q2 | 31.18 Million KRW | -29.37% |
| 2022 Q1 | 44.15 Million KRW | 363.78% |
| 2022 FY | 181.8 Million KRW | 1809.78% |
| 2022 Q4 | 181.8 Million KRW | 6.52% |
| 2022 Q3 | 170.67 Million KRW | 447.3% |
| 2021 Q2 | 33.18 Million KRW | -47.88% |
| 2021 FY | 9.51 Million KRW | -92.7% |
| 2021 Q4 | 9.51 Million KRW | -45.19% |
| 2021 Q1 | 63.67 Million KRW | -51.16% |
| 2021 Q3 | 17.36 Million KRW | -47.66% |
| 2020 Q2 | 260.93 Million KRW | 164.58% |
| 2020 Q1 | 98.61 Million KRW | -22.04% |
| 2020 Q3 | 189.01 Million KRW | -27.56% |
| 2020 FY | 130.38 Million KRW | 3.07% |
| 2020 Q4 | 130.38 Million KRW | -31.02% |
| 2019 Q2 | 182.19 Million KRW | -8.22% |
| 2019 Q4 | 126.5 Million KRW | -18.04% |
| 2019 FY | 126.5 Million KRW | 0.0% |
| 2019 Q1 | 198.5 Million KRW | 0.0% |
| 2019 Q3 | 154.34 Million KRW | -15.28% |
| 2018 FY | - KRW | 0.0% |
| 2018 Q2 | - KRW | 0.0% |
| 2018 Q4 | - KRW | 0.0% |
| 2018 Q1 | - KRW | 0.0% |
| 2018 Q3 | - KRW | 0.0% |
| 2017 Q3 | - KRW | 0.0% |
| 2017 Q1 | - KRW | 0.0% |
| 2017 FY | - KRW | 0.0% |
| 2017 Q4 | - KRW | 0.0% |
| 2017 Q2 | - KRW | 0.0% |
| 2016 Q3 | - KRW | 0.0% |
| 2016 FY | - KRW | 0.0% |
| 2016 Q4 | - KRW | 0.0% |
| 2016 Q2 | - KRW | 0.0% |
| 2016 Q1 | - KRW | 0.0% |
| 2015 Q2 | - KRW | 0.0% |
| 2015 Q3 | - KRW | 0.0% |
| 2015 Q4 | - KRW | 0.0% |
| 2015 FY | - KRW | 0.0% |
| 2015 Q1 | - KRW | 0.0% |
| 2014 Q3 | - KRW | 0.0% |
| 2014 Q2 | - KRW | 0.0% |
| 2014 FY | - KRW | 0.0% |
| 2014 Q4 | - KRW | 0.0% |
| 2014 Q1 | - KRW | 0.0% |
| 2013 Q3 | - KRW | 0.0% |
| 2013 Q4 | - KRW | 0.0% |
| 2013 FY | - KRW | 0.0% |
| 2013 Q1 | - KRW | 0.0% |
| 2013 Q2 | - KRW | 0.0% |
| 2012 Q4 | - KRW | 0.0% |
| 2012 Q3 | - KRW | 0.0% |
| 2012 Q2 | - KRW | 0.0% |
| 2012 FY | - KRW | 0.0% |
| 2012 Q1 | - KRW | 0.0% |
| 2011 Q3 | - KRW | 0.0% |
| 2011 Q1 | 3.03 Billion KRW | 8.27% |
| 2011 Q2 | - KRW | -100.0% |
| 2011 FY | - KRW | -100.0% |
| 2011 Q4 | - KRW | 0.0% |
| 2010 Q2 | - KRW | 0.0% |
| 2010 Q1 | - KRW | 0.0% |
| 2010 Q4 | 2.8 Billion KRW | 0.0% |
| 2010 Q3 | - KRW | 0.0% |
| 2010 FY | 2.8 Billion KRW | 0.0% |
| 2009 Q4 | - KRW | 0.0% |
| 2009 Q3 | - KRW | 0.0% |
| 2009 Q2 | - KRW | 0.0% |
| 2009 Q1 | - KRW | 0.0% |
| 2009 FY | - KRW | 0.0% |
| 2008 Q1 | - KRW | 0.0% |
| 2008 Q2 | - KRW | 0.0% |
| 2008 FY | - KRW | 0.0% |
| 2008 Q3 | - KRW | 0.0% |
| 2008 Q4 | - KRW | 0.0% |
| 2007 Q2 | - KRW | 0.0% |
| 2007 Q3 | - KRW | 0.0% |
| 2007 FY | - KRW | 0.0% |
| 2007 Q4 | - KRW | 0.0% |
| 2007 Q1 | - KRW | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 13.64 Billion KRW | 99.123% |
| Dong-A Socio Holdings Co., Ltd. | 202.06 Billion KRW | 99.941% |
| Ildong Holdings Co., Ltd. | 29.87 Billion KRW | 99.599% |
| HANDOK Inc. | 123.78 Billion KRW | 99.903% |
| Kukje Pharma Co., Ltd. | 475.74 Million KRW | 74.844% |
| Yuhan Corporation | 60.23 Billion KRW | 99.801% |
| Dong-A ST Co., Ltd. | 161.99 Billion KRW | 99.926% |
| SAMSUNG PHARM. Co., LTD. | 101.81 Million KRW | -17.542% |
| Hanmi Pharm. Co., Ltd. | 82.02 Billion KRW | 99.854% |
| Hanall Biopharma Co.,Ltd | 590.3 Million KRW | 79.726% |
| Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | 98.022% |
| Dong Sung Bio Pharm.Co.,Ltd. | 18.52 Billion KRW | 99.354% |
| MYUNGMOON Pharm co.,Ltd | 12.58 Billion KRW | 99.049% |
| Hana Pharm Co., Ltd. | 1.59 Billion KRW | 92.515% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | 99.123% |
| REYON Pharmaceutical Co., Ltd. | 121 Billion KRW | 99.901% |
| Aprogen pharmaceuticals,Inc. | 32 Billion KRW | 99.626% |
| JW Holdings Corporation | 20.65 Billion KRW | 99.421% |
| Ildong Pharmaceutical Co., Ltd. | 14.82 Billion KRW | 99.193% |
| Chong Kun Dang Pharmaceutical Corp. | 30 Billion KRW | 99.601% |
| JW Pharmaceutical Corporation | 30 Billion KRW | 99.601% |
| Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | 45.343% |
| Hyundai Pharmaceutical Co., Ltd. | 580.64 Million KRW | 79.389% |
| Samil Pharmaceutical Co.,Ltd | 49.56 Billion KRW | 99.759% |
| Jeil Pharmaceutical Co.,Ltd | 4.45 Billion KRW | 97.312% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | 99.123% |
| Kwang Dong Pharmaceutical Co., Ltd. | 19.02 Billion KRW | 99.371% |
| Daewoong pharmaceutical Co.,Ltd | 93.41 Billion KRW | 99.872% |
| JW Pharmaceutical Corporation | 30 Billion KRW | 99.601% |
| Yuhan Corporation | 60.23 Billion KRW | 99.801% |
| Jeil Pharma Holdings Inc | 10.5 Billion KRW | 98.86% |
| Yungjin Pharm. Co., Ltd. | 40.37 Billion KRW | 99.704% |
| Suheung Co., Ltd. | 74 Billion KRW | 99.838% |
| JW Pharmaceutical Corporation | 30 Billion KRW | 99.601% |
| Samjin Pharmaceuticals Co., Ltd. | 4.16 Billion KRW | 97.128% |
| Korea United Pharm Inc. | 10.96 Billion KRW | 98.908% |
| CKD Bio Corp. | 69.43 Billion KRW | 99.828% |
| Daewon Pharmaceutical Co., Ltd. | 34.57 Billion KRW | 99.654% |
| Dongwha Pharm.Co.,Ltd | 16.12 Billion KRW | 99.258% |
| Whan In Pharm Co.,Ltd. | 307.05 Million KRW | 61.024% |
| Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | 45.343% |
| Chong Kun Dang Holdings Corp. | 72.11 Billion KRW | 99.834% |
| Boryung Corporation | 151.7 Billion KRW | 99.921% |
| Bukwang Pharmaceutical Co., Ltd. | 78.52 Billion KRW | 99.848% |
| Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | 98.022% |
| JW Lifescience Corporation | 168 Million KRW | 28.763% |